Keyword: GenSight Biologics
In our EuroBiotech roundup this week, Hookipa prices IPO, Affimed eyes end of clinical hold and Cassiopea posts hair loss data.
The AAV gene therapy was no better than placebo at improving vision at 48 weeks, leading GenSight to look to future updates to salvage the study.
GenSight has new data from its phase 3 program for its gene therapy for rare eye disease LHON, sparking another rise in its share price.
Aron Knickerbocker will helm Five Prime, Hallberg becomes Sobi's general counsel, Truckenmiller promoted to EMD Serono's SVP.
Parisian gene therapy biotech GenSight says its chief medical officer, Mohamed Genead, M.D., has stepped down for “personal reasons.”
GenSight Biologics has raised €22.5 million to prepare to bring gene therapy GS010 to market in the U.S. and Europe.
Novartis-backed gene therapy player GenSight is looking to bounce back from its failure to list on Nasdaq by pulling off a €40 million IPO in Paris.
Another day, another ditched IPO--this time for gene therapy specialist GenSight Biologics that pulled its attempt to go public this week, citing “market conditions.”